Busulfex

Busulfex is a brand name of busulfan, approved by the FDA in the following formulation(s):

BUSULFEX (busulfan - injectable; injection)

• 
  Manufacturer: OTSUKA PHARM
  
  Approval date: February 4, 1999
  
  Strength(s): 6MG/ML ^[RLD]

Has a generic version of Busulfex been approved?

No. There is currently no therapeutically equivalent version of Busulfex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Busulfex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Parenteral busulfan for treatment of malignant disease
  Patent 5,430,057
  Issued: July 4, 1995
  Inventor(s): Andersson; Borje S. & Bhagwatwar; Harshal P. & Chow; Diana S. L.
  Assignee(s): Board of Regents, The University of Texas System
  University of Houston-University Park
  Stable parenteral formulations of busulfan safe for parenteral administration are disclosed that exhibit improved bioavailability and optimize high dose busulfan therapy against malignant disease.
  
  Patent expiration dates:
  
  
  • September 30, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
  
  
  
  • March 30, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
    ✓ 
    Pediatric exclusivity
  
  



• 
  Parenteral busulfan for treatment of malignant disease
  Patent 5,559,148
  Issued: September 24, 1996
  Inventor(s): Andersson; Borje S. & Bhagwatwar; Harshal P. & Chow; Diana S.
  Assignee(s): Board of Regents, The University of Texas System
  University of Houston-University Park
  Stable parenteral formulations of busulfan for parenteral administration are disclosed. The improved bioavailability of the parenteral formulations optimizes high dose busulfan therapy against malignant disease and improves the safety of such therapy.
  
  Patent expiration dates:
  
  
  • September 30, 2013
    
    ✓ 
    Patent use: METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
  
  
  
  • March 30, 2014
    
    ✓ 
    Patent use: METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Busulfex Consumer Information (Wolters Kluwer)
• Busulfex Consumer Information (Cerner Multum)
• Busulfex Advanced Consumer Information (Micromedex)
• Busulfan Consumer Information (Wolters Kluwer)
• Busulfan Tablet Consumer Information (Wolters Kluwer)
• Busulfan Consumer Information (Cerner Multum)
• Busulfan Intravenous Advanced Consumer Information (Micromedex)
• Busulfan AHFS DI Monographs (ASHP)

MabThera

Mabthera may be available in the countries listed below.

UK matches:

• Mabthera 100mg and 500mg concentrate for solution for infusion (SPC)

Ingredient matches for Mabthera

Rituximab

Rituximab is reported as an ingredient of Mabthera in the following countries:

• Albania


• Argentina


• Aruba


• Australia


• Austria


• Bahrain


• Bangladesh


• Belarus


• Belgium


• Bosnia & Herzegowina


• Brazil


• Chile


• China


• Colombia


• Croatia (Hrvatska)


• Cuba


• Cyprus


• Czech Republic


• Denmark


• Dominican Republic


• Ecuador


• Egypt


• Estonia


• Finland


• France


• Georgia


• Germany


• Greece


• Hong Kong


• Hungary


• Iceland


• India


• Indonesia


• Iran


• Iraq


• Ireland


• Israel


• Italy


• Jamaica


• Japan


• Jordan


• Kazakhstan


• Kuwait


• Lebanon


• Lithuania


• Luxembourg


• Macedonia


• Malaysia


• Mexico


• Morocco


• Nepal


• Netherlands


• New Zealand


• Norway


• Oman


• Pakistan


• Philippines


• Poland


• Portugal


• Qatar


• Romania


• Russian Federation


• Saudi Arabia


• Serbia


• Singapore


• Slovakia


• Slovenia


• South Africa


• Sri Lanka


• Sweden


• Switzerland


• Syria


• Taiwan


• Thailand


• Trinidad & Tobago


• Tunisia


• Turkey


• Ukraine


• United Arab Emirates


• United Kingdom


• Uruguay


• Venezuela


• Yemen

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.